TKNO — Stock Film
STOCK FILMSCENE 1/11TKNO · $7.00
Stock Expert AI presents
TKNO
Alpha Teknova, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Alpha Teknova, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 158 employees. Now — the numbers.

on the stock market since 2021
158 employees
$284.2M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.4.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
77%Lab Essentials
Lab Essentials 77%Clinical Solutions 19%Other Product 5%
77% of all revenue comes from a single line: Lab Essentials.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $15.1M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
15 buy2 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
40
weak

Clearly below the class average.

FINANCIAL STRENGTH
49
weak

Clearly below the class average.

VALUATION
52
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
34
very weak

Clearly below the class average.

PRICE MOMENTUM
95
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
The product is selling

Sales run at $40.5M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 15 buys and 2 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $17.3M against $40.5M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, TKNO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: TKNO is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film